The Delta4 3D dose verification device was commissioned in the current work for pre-treatment quality assurance (QA) of Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) plans. The cross calibration and relative array calibration were performed to enable absolute dose comparison. The linearity of response with dose and temperature sensitivity tests were also conducted to investigate dosimetric properties of the Delta4 device. The need to modify the original CT image of the Delta4 phantom for accurate dose calculation and comparison is addressed in this work, applying a CT extension algorithm. A number of test plans varying from simple 4—field conformal to IMRT and VMAT plans were measured to evaluate the accuracy of this device. It was found that the Delta4 device measured dose accurately to within ±1%. In order to maintain this level of accuracy the machine output fluctuations need to be corrected prior to each measurement and the relative array calibration needs to be performed every six months.
Increasing interest in the implementation of arc therapy, a radiotherapy technique in which the gantry of the linear accelerator is rotating while delivering the radiation dose to the patient, has triggered questions regarding the way quality assurance (QA) should be carried out for patient treatment plans. Arc therapy is another form of intensity modulated radiotherapy (IMRT) [
The dosimetric properties of the Delta4 device were investigated by Sadgopan et al. in 2009 [
Feygelman et al. [
A comparison between the Delta4 device and traditional film and ionisation chamber IMRT QA results for 5 clinical tomotherapy IMRT plans was reported by Guert et al. in 2009 [
Bedford et al. 2009 [
Quality assurance of RapidArc (a trade mark term used by the linac manufacturer Varian to refer to arc therapy) plans using Delta4 was also reported by Korreman et al. in 2009 [
Feygelman et al. [
Fotina et al. 2011 [
The use of the Delta4 device for IMRT and VMAT patient pre-treatment quality assurance has been validated in the current work. While there is a similarity between the tests completed in this work and in the published literature, an additional procedure implemented in this work (to allow for a more realistic comparison between the planned and measured dose maps) was not reported previously. This procedure involved modification of the manufacturer provided computed tomography (CT) images of the Delta4 phantom. These images are used in the TPS for dose calculation. This step will be described in this report in addition to the calibration and characterisation tests prior to the clinical implementation of the Delta4 device. In addition, to our knowledge there are only 6 devices in clinical use at present in Australia and New Zealand. With the increase in VMAT use, the need for 3D dosimetric verification devices will increase as well. The authors believe that the readers will benefit from the information provided in this work.
Delta4 is capable of measuring absolute dose in the cylindrical PMMA phantom. The measurement is synchronised with the linear accelerator (linac) by detecting the trigger pulse signal from the linac. In order to ensure that the dose is measured accurately and to gain a full understanding of the features and limitations of Delta4, the following tests were performed:
1) Cross calibration with ionisation chamber;
2) Detector response calibration;
3) Linearity check;
4) Directional response correction;
5) Temperature response check;
6) Four fields plan verification;
7) IMRT and VMAT plan verification.
Cross calibration of the Delta4 detector was performed against the reference NE2571 Farmer ionisation chamber with a known dose calibration factor traceable to ARPANSA [
In the second measurement, the Delta4 detector planes were disassembled from the cylindrical phantom so that they could be placed in another solid phantom jig. This jig was also designed by the vendor to place the detector planes at a water equivalent depth of 5 cm. Both the reference Farmer chamber and the Delta4 detector planes were irradiated with the same number of monitor units (100 MU), dose rate (600 MU/min), 10 × 10 cm2 radiation field size, 95 cm source to surface distance (SSD) and 100 cm source to chamber distance (SCD).
The TRS 398 formalism was adopted for dose calculations. For the measurement performed with the NE2571 Farmer chamber at a depth of 5 cm water, the dose was calculated as follows:
where kTP is the correction factor which accounts for changes in the collected charge due to the variation of temperature and pressure in the atmosphere; ks is the recombination factor and kp is the polarity correction factor.
is the charge to absorbed dose in water calibra tion factor and M1 is the average charge collected in three measurements.
The absorbed dose in water as measured by the Farmer chamber was entered into the Delta4 program. The dose calibration factor CFD was then calculated based on the response (R) of the diode detectors as measured during the cross calibration as follows:
This factor has unit of diode response per cGy. The absorbed dose in water DDelta4 as measured by the Delta4 detector can therefore be derived from the measured response of the Delta4 diode detectors in any measurement condition as follows:
The 1069 diode detectors do not have the same response even for the same irradiation conditions. The non-uniformity in response of the Delta4 detectors can be corrected by the software using the data acquired from the discussed procedure below.
the same setup as for the cross calibration except the field size was changed from 10 × 10 cm2 to 26 × 26 cm2 to cover all the detectors. The measurement was performed over 7 different positions A, B, C, D, E, F and G as shown in
The Delta4 detectors were checked for linearity in response as a function of the linac output (or Monitor Units). The measurement was setup in the exact same way as for the patient specific QA measurement used at our centre. The source to detector distance (SDD) is 100 cm and the centre of the Delta4 phantom was setup using the lateral lasers and the cross hair. The linearity check was performed using a range of MUs from 4 - 500. This range of MUs was chosen because it had been verified previously that the linear accelerator dose output is linear within this range. The linearity index for a particular monitor unit MU (IMU) was calculated using the following formula:
where RMU is the dose output measured with a particular monitor MU and R100 is the dose output measured with 100 MU.
The linearity index was calculated for each detector and MU of 4, 5, 10, 50, 100, 250 and 500. The percentage of detectors that has linearity index less than and equal to 1% for each MU was plot on the bar graph to assess the linearity response of the Delta4 detectors.
The response of the detector planes in the Delta4 cylindrical phantom is different at different beam gantry angles. This is caused by the additional attenuation through the Printed Circuit Board (PCB) underneath the diode detectors. The PCB was observed in the CT image of the Delta4 phantom. The maximum difference in the detector response occurs between opposing beams that are normal to the detector plane. This maximum difference was measured using the same setup as in the relative array calibration (refer to
It was found that the diode detector response varies with temperature [
Once the cross calibration and the dosimetric characteristic tests for the Delta4 had been performed, the accuracy of absorbed dose measurement with a clinical plan delivery was assessed. This was investigated using a 20 × 20 cm2 radiation field and irradiating the detector at gantry angles at 0, 90, 270 and 180 degrees with equal beam weighting. Two plans were generated with a prescription of 20 MU and 200 cGy to a point respectively. The 20 MU prescription was investigated because this is the minimum MU where the Delta4 detectors showed linearity in their response. The absorbed dose in the Delta4 phantom was calculated by the Pinnacle TPS [
The absorbed dose in the Delta4 phantom from the 4- field plan was measured using the SAD setup. The centre of the phantom was aligned to the linac iso-centre using the lateral and sagittal lasers. The calibration field was measured prior to the 4-field plan to obtain the Daily Correction Factor (DCF). The DCF serves 2 purposes; it corrects for the variation of the linac output and reduces the uncertainty in the measured dose due to the uncertainty in estimating the physical density of the Delta4 phantom. The DCF was calculated by the software based on the planned and measured dose in the Delta4 phantom using the same setup and beam parameters. In this work the setup was as per the 4-field plan except 200 MU was used at a single gantry angle of 0˚.
Since the primary use of Delta4 is to perform pre-treatment dose verification check for IMRT and VMAT plans, it is essential that in the commissioning process these types of plan are checked prior to releasing Delta4 for clinical use. For this purpose, two clinical head and neck IMRT plans and one non-clinical prostate VMAT plan were used (VMAT function in the planning system had not been commissioned for clinical used at the time). These plans were initially created on a real patient CT density map and then copied into the cylindrical Delta4 phantom CT density map. The head and neck case was chosen because it had a large number of control points, a large range of segment sizes and intensity modulation. This made it easier to investigate issues with small field dosimetry and high dose gradient regions. The VMAT plan on the other hand was chosen to investigate the feasibility of VMAT delivery on our new Elekta Synergy linac and also to see how well the plan and delivered doses agreed.
The CT image size of the Delta4 phantom provided by the vendor was smaller than the patient CT image size (comparing Figures 3(a) and (d)). When importing the Delta4 phantom into pinnacle to create a QA plan, the same image size was maintained (
The problem shown in
The absorbed dose in the PMMA phantom as measured by the NE2571 farmer chamber in the cross calibration procedure was 0.947 Gy. This was 2.5% higher than the absorbed dose measured with the same setup in liquid water. This difference was expected because of the following error contributing factors estimated by the IAEA TRS 398 dosimetry protocol [
As mentioned in the previous section a calibration field measurement is required prior to the pre-treatment QA measurement. By using the calibration field, the uncertainty due to both the fluctuation in the beam output and the use of an estimated density value of the Delta4 phantom can be minimised. The total uncertainty in measuring dose using the Delta4 device is then reduced to ±1.7%.
The manufacturer acceptance criteria for the array calibration are that 90% of the detectors should have responses within ±0.5% of each other and none of the detectors should have a response different greater ±2% for the same dose. In this commissioning work, 91% of the Wing units detectors were within ±0.5% and 100% of the Main unit detectors were within ±0.5% Another acceptance criterion for this response test is that all detectors should have signal strength greater than 70% relative to the central detector. It was observed in this work that all of the detectors in the Main and Wings Units measured signal more than or equal to 85% and 87% relative to the signal strength of the central detector respectively.
It can be seen from
at 4 MU. Only 1.1% number of detectors has linearity index greater than 1% when 5 MU were used. The linearity indices for higher MU were also analysed, but are not shown in this report, showed that none of the detector in the Delta4 phantom has linearity index greater than 1. It was therefore decided that 5 MU is the minimum MU to be used for each segment in the clinical IMRT plan.
It was reported in the Delta4 user manual that the directional response correction factor makes at most ±0.5% difference to the final dose measurement result. Since this is a minor correction, no further investigation was performed to verify the reported result in this work. However, to maximise the accuracy of the Delta4 detector, the directional response correction was measured and decided to apply in all future quality assurance measurements.
It was found that the signal changed linearly with temperature. A temperature change of 2.5 degree Celsius changes the signal by 0.65% that is 0.26%/˚C. The decrease in temperature results in an increase in the signal.
The DVH, gamma analysis and detector point dose were compared against the Pinnacle3 planned dose in Delat4 phantom. The DVH in
A gamma analysis was also performed for planned and measured doses in the detector plane of the Delta4 phantom. Figures 6(a) and (b) show the gamma results for 5 MU per field and 2 Gy prescriptions respectively. The criteria set for the gamma analysis are 3% and 3 mm for dose and distance-to-agreement conditions respectively with a dose threshold of 30% of the prescription dose. The results in
Point to point dose comparison was carried out for these 2 prescriptions. Various planned and measured profiles across the detector planes are shown in Figures 7-10.
Comparison between the planned and measured doses at other positions (Figures 8-10) in the Delta4 detector planes showed that agreement within 1% can be achieved at all positions indicated by the blue line in these figures. It was noticed for both the in-plane and the cross-plane direction that the discrepancy between the planned and measured doses increases for those detectors that are further away from the centre of the phantom.
Figures 11-13 show the gamma analysis and DVHs for the clinical head and neck and prostate cases planned in IMRT mode and prostate case planned in Smart Arc mode in Pinnacle TPS. The dose deviation, DD (left), distance-to-agreement DTA (middle), and gamma index (right) for these comparisons are displayed together for each patient plan. Delta4 software calculated these results based on the algorithm reported by Low et al. 1998 [
Figures 11 and 12 show that the dose deviation results for the head and neck plans were well under the 90% pass rate. This is because of a large number of high dose gradient regions in the Head and Neck plan which were created in response to multiple critical organ dose limits in the vicinity of the tumour. The high percentage in the DTA result implies that the setup error is small. The gamma analysis incorporates both the dose deviation and distance to agreement to account for the high dose gradient in the treatment plan. It can be seen that the gamma result for these head and neck plans passed the 90% level, in fact better 95% level were achieved. The VMAT prostate plan result (
The ScandiDos Delta4 phantom for 3D dose verification has been commissioned and met the criteria to be used clinically. The cross calibration, relative measurement, linearity and directional response correction were performed. Based on these measurements, the uncertainty in the dose measurement using the Delta4 phantom was estimated to be ±1.7%. This uncertainty is result in part from the error in the cross-calibration process. The comparison between Pinnacle calculated and Delta4 phantom dose for a simple four orthogonal fields plan was carried out to assess the accuracy of the Delta4 phantom and also to establish a baseline. It was found that agreement of ±1% between the planned and measured doses was achieved for most detectors in the phantom except for the outer most row and column detectors. In addition, the Gamma analysis of these four fields plan results show that 100% of the data points had a gamma index less than 1 for the 3% and 3 mm dose and distance-to-agreement criteria.
Additional tests were performed to study the detector response with room temperature. Because of the significant change in the detector signal with temperature (0.26%/˚C), it is essential that the temperature is entered into the software before the measurement takes place. Based on experiences gained during the commissioning process, it is also recommended that in order to maintain the uncertainty in measuring the absolute dose, routine quality assurance needs to be performed for the Delta4 phantom. The cross calibration should be performed every year or after the beam output has been adjusted. The detector sensitivity is expected to change due to radiation damage. The manufacturer has specified a change of less than 1% over 1000 Gy. We expect to treat roughly about 10 patients per week. To keep the uncertainty due to radiation damage well under 1%, it was decided that the sensitivity correction and linearity should be performed every six months.
Prior to releasing the Delta4 device for clinical use, two head and neck IMRT and one VMAT plan were trialled. All of these plans were passed well above the 95% level when using the gamma criteria of 3% and 3 mm and the dose threshold 30%. It was found that the use of dose deviation analysis alone was not sufficient to determine whether the plan passed or failed. The same gamma analysis criteria were decided to be used for as-
sessing future clinical plans.
I would also like to thank the medical physics team at the Nepean Cancer Care Centre for contributing ideas for this project in many of our physics meetings. I also like to thank Associated Professor Eva Bezak for her great effort in the editing process of this paper. Finally, I would to acknowledge Dr. Paul Reich for his idea in building the Matlab code that was used in this work and Dr. Scott Penfold and Joshua Moorrees for doing the proof reading.